Kidney Cancer Coverage From Every Angle

miR-181a Upregulation and KLF6 Expression in Clear Cell Renal Cell Carcinoma

By: Joseph Cupolo
Posted: Tuesday, December 5, 2017

Although dysregulated expression of miR-181a has been found to play a role in tumorigenesis in many cancers, its role in clear cell renal cell carcinoma has not been identified. However, a study by Xu Zhang, MD, and colleagues at the Chinese People’s Liberation Army Medical School in Beijing may have shed some light on the upregulation of miR-181a in clear cell renal cell carcinoma. The study, published in Urologic Oncology, found a relationship between levels of miR-181a and KLF6 expression, suggesting that manipulating miR-181a “may provide a beneficial effect in the treatment of clear cell renal cell carcinoma.”

The investigators discovered that miR-181a expression was upregulated in clear cell renal cell carcinoma tissues and cell lines. They also noted that the expression level of miR-181a correlated with the tumor size, tumor/node/metastasis staging, and Fuhrman grade. “Overexpression of miR-181a led to reduced KLF6 mRNA and protein levels, whereas mutations of the potential miR-181a–binding sites in the KLF6 gene abrogated this inhibitory effect,” they explained.

Expression levels of miR-181a in samples of clear cell renal cell carcinoma tumors and adjacent nontumor tissues from 42 patients as well as in 786-O, 769-P, A498, and CAKI-1 clear cell renal cell carcinoma cell lines were determined by quantitative real-time polymerase chain reaction. Potential targets of miR-181a were predicted using bioinformatic approaches and then verified by using the luciferase reporter assay. 

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.